Roivant Sciences Ltd. (ROIV)
41.85
+0.66
(+1.60%)
USD |
NASDAQ |
Nov 11, 16:00
41.03
-0.82
(-1.96%)
After-Hours: 20:00
Roivant Sciences EPS Diluted (Quarterly) : -0.2869 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -0.2869 |
| June 30, 2026 | -0.2634 |
| March 31, 2026 | 0.373 |
| December 31, 2025 | -0.3816 |
| September 30, 2025 | -0.1667 |
| June 30, 2025 | -0.3283 |
| March 31, 2025 | -0.2919 |
| December 31, 2024 | 0.2344 |
| September 30, 2024 | -0.313 |
| June 30, 2024 | 0.1219 |
| March 31, 2024 | -0.1882 |
| December 31, 2023 | 6.035 |
| Date | Value |
|---|---|
| September 30, 2023 | -0.3951 |
| June 30, 2023 | -0.3843 |
| March 31, 2023 | -0.0453 |
| December 31, 2022 | -0.4935 |
| September 30, 2022 | -0.4166 |
| June 30, 2022 | -0.4768 |
| March 31, 2022 | -0.3899 |
| December 31, 2021 | -0.4144 |
| September 30, 2021 | -0.3206 |
| June 30, 2021 | -0.3701 |
| March 31, 2021 | -2.288 |
| March 31, 2020 | -0.2771 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Bicycle Therapeutics Plc | -0.1497 |
| Immunovant, Inc. | -0.4705 |
| Adaptimmune Therapeutics Plc | -- |
| Kiniksa Pharmaceuticals International Plc | 0.5575 |
| Autolus Therapeutics Plc | -0.2068 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -152.97M |
| Revenue (Quarterly) | 35.12M |
| Total Expenses (Quarterly) | 242.50M |
| Enterprise Value | 26.76B |
| Gross Profit Margin (Quarterly) | 88.75% |
| Profit Margin (Quarterly) | -435.6% |
| Earnings Yield | -1.34% |
| Normalized Earnings Yield | -3.087 |